Molecular reprogramming in thymic neuroendocrine tumors: a narrative review
Authors:
- Jing DiJing Di
- Yijia ZhouYZYijia Zhou
- Jingjing HuJHJingjing Hu
Open Access
- 1 December 2025
- journal article
- Published by AME Publishing Company in Mediastinum
- Vol. 9, 32
Abstract
Background and Objective: Thymic neuroendocrine tumors (tNETs) are rare and heterogeneous neoplasms with limited evidence to guide diagnosis and management. Traditional classifications rely heavily on morphology, but recent advances in molecular profiling have begun to reshape understanding of their biology and clinical behavior. This narrative review synthesizes recent molecular findings in tNETs and proposes an integrated framework that combines traditional morphology with molecular stratification to guide precision oncology. Methods: We performed a narrative review of the current literature on tNETs, focusing on histologic classification, molecular taxonomy, diagnostic algorithms, and therapeutic strategies. Special emphasis was placed on integrating emerging evidence from genomic, epigenetic, and clinical studies published between 2010 and 2025. Key Content and Findings: Molecular frameworks such as copy number instability (CNI)-based classification, together with recurrent alterations in MEN1, TP53, and RB1, are refining risk stratification and linking tNETs to neuroendocrine neoplasms in other organ systems. Therapeutic advances include the use of everolimus and temozolomide, while PRRT appears less effective in this subgroup. Epigenetic dysregulation and novel trial designs, including basket and adaptive studies, represent promising avenues for future research. Conclusions: This review integrates current knowledge of tNETs with recent advances in molecular diagnostics and therapeutic strategies. By highlighting key genetic and epigenetic alterations, as well as future directions such as liquid biopsy, artificial intelligence, and novel trial designs, we emphasize the need for biomarker-driven approaches to improve outcomes in this ultra-rare disease.Keywords
This publication has 38 references indexed in Scilit:
- Molecular Classification of Neuroendocrine Tumors of the ThymusJournal of Thoracic Oncology, 2019
- Genomic Analysis of Thymic Epithelial Tumors Identifies Novel Subtypes Associated with Distinct Clinical FeaturesClinical Cancer Research, 2017
- Frequent silencing of RASSF1A by DNA methylation in thymic neuroendocrine tumoursLung Cancer, 2017
- The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and ChangesJournal of Thoracic Oncology, 2015
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Neuroendocrine Thymic Carcinoma Metastatic to the Parathyroid Gland that was Reimplanted into the Forearm in Patient with Multiple Endocrine Neoplasia Type 1 Syndrome: A Challenging Management DilemmaEndocrine Practice, 2013
- Treatment, prognostic markers and survival in thymic neuroendocrine tumours. A study from a single tertiary referral centreLung Cancer, 2013
- Frequent Promoter Hypermethylation of the APC and RASSF1A Tumour Suppressors in Parathyroid TumoursPLOS ONE, 2010
- Thymic Neuroendocrine Carcinoma (Carcinoid) in Multiple Endocrine Neoplasia Type 1 Syndrome: The Italian SeriesThe Journal of Clinical Endocrinology & Metabolism, 2005
- Comparative genomic hybridization analysis of thymic neuroendocrine tumorsLaboratory Investigation, 2005